![Mark Vickery Mark Vickery](https://staticx.zacks.com/images/mugshots/mark_vickery/mark_vickery-8.png)
Top Research Reports for Target, Illumina & T-Mobile US
![](https://staticx.zacks.com/images/zt/ztNow_icon2.png)
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Friday, September 20, 2019
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Target (TGT), Illumina (ILMN) and T-Mobile US (TMUS). These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
You can see all of today’s research reports here >>>
Target’s shares have outperformed the Zacks Retail- Discount & Variety industry in the year-to-date period (63.2% vs. 39.5%). The Zacks analyst thinks that the company is fast acclimatizing with the changing retail ecosystem and deploying resources to enhance omni-channel capacities, come up with new brands, remodel stores and expand same-day delivery options.
These bode well for the company that posted better-than-expected second-quarter fiscal 2019 results, wherein both the top and the bottom lines grew year over year. The company witnessed healthy traffic and impressive comparable digital channel sales. Sturdy performance prompted management to lift fiscal 2019 earnings view.
Management now envisions comparable sales to increase about 3.4% both in the third quarter and in the second half. However, we believe that incremental investments, higher wages and rise in costs due to new fulfillment options may squeeze margins.
(You can read the full research report on Target here >>>)
Shares of Illumina have lost 4.4% in the past six months, outperforming the Zacks Medical - Biomedical and Genetics industry’s fall of 12.2%. The Zacks analyst believes llumina continues to put up a robust performance across a broad range of sequencing applications.
The launch of Veriseq NIPT v2 and the company’s partnership with AnchorDx in the second quarter also drive optimism. Over the past year, Illumina’s shares have been outperforming the industry it belongs to. With respect to quarterly results, Illumina exited the second quarter of 2019 on a solid note, with earnings and revenues beating the Zacks Consensus Estimate.
It is encouraging to note that revenues grew across the company’s high and low throughput categories. On the flip side, contraction in both margins and a year-over-year decline in Service and Other Revenues are concerns.
(You can read the full research report on Illumina here >>>).
T-Mobile US’ shares have gained 7% in the past three months, underperforming the Zacks National Wireless industry’s rise of 7.9% over the same period. The Zacks analyst believes that the New T-Mobile will have about 127 million customers and a strong closing balance sheet, and is expected to heighten competition in the 5G space.
T-Mobile has cleared most of the regulatory and shareholder approvals for its game-changing merger with Sprint. T-Mobile continues to invest in its network and prepare for nationwide 5G with the aggressive rollout of its 600 MHz spectrum. The wireless carrier has introduced 5G millimeter wave network in six cities including New York and Los Angeles.
However, a highly competitive and saturated U.S. wireless market remains a major headwind. Intensifying competition is likely to limit its ability to attract and retain customers and may affect operating results. The company launched several low-priced service plans which have enhanced its revenues, but not significantly improved the bottom line.
(You can read the full research report on T-Mobile US here >>>).
Other noteworthy reports we are featuring today include DuPont de Nemours (DD), Xcel Energy (XEL) and Regeneron Pharmaceuticals (REGN).
Just Released: Zacks’ 7 Best Stocks for Today
Experts extracted 7 stocks from the list of 220 Zacks Rank #1 Strong Buys that has beaten the market more than 2X over with a stunning average gain of +24.6% per year.
These 7 were selected because of their superior potential for immediate breakout.
See these time-sensitive tickers now >>
Mark Vickery
Senior Editor
Note: Sheraz Mian heads the Zacks Equity Research department and is a well-regarded expert of aggregate earnings. He is frequently quoted in the print and electronic media and publishes the weekly Earnings Trends and Earnings Preview reports. If you want an email notification each time Sheraz publishes a new article, please click here>>>
Get the latest research report on REGN - FREE
Get the latest research report on XEL - FREE
Get the latest research report on TGT - FREE
Get the latest research report on DD - FREE
Get the latest research report on ILMN - FREE
Get the latest research report on TMUS - FREE